Sacituzumab tirumotecan for previously treated advanced biliary tract cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, sacituzumab tirumotecan, for people with advanced biliary tract cancer that has stopped responding to previous treatments. It works by targeting a protein called TROP2 on cancer cells. This may be an option if your cancer has progressed and you meet the health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your biliary tract cancer must have worsened after at least one prior treatment, or you couldn't tolerate that treatment.
- You must have a measurable tumor (one that can be seen on scans).
- You must be physically active enough to do light work or be fully active (ECOG 0 or 1).
- Your tumor must have at least a low level of the TROP2 protein (tested on a biopsy).
- Your liver, kidney, and blood counts must meet specific healthy levels (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, sacituzumab tirumotecan, for people with advanced small bowel adenocarcinoma that has not responded to or cannot tolerate platinum-based chemotherapy. The drug targets a protein called TROP2 on cancer cells to deliver treatment directly to them.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests a new two-drug combination (sacituzumab tirumotecan and envafolimab) for people with advanced bile duct or gallbladder cancer that has already been treated with immunotherapy plus chemotherapy. It aims to see if these drugs can shrink or control the cancer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
This clinical trial tests a new drug called Sacituzumab Tirumotecan given before surgery to women with an aggressive type of early-stage breast cancer (triple-negative breast cancer, or TNBC). The goal is to see if it can improve treatment outcomes.
Hear when a new Advanced Biliary Tract Cancer(BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.